Payment overview · 2025
General Payments
$32.38
2 reported records · 2 companies
Healthcare provider profile · identity verified
Glenn Beck, DO
Allopathic & Osteopathic Physicians|Family Medicine · PAINESVILLE, OH · NPI 1851484752
Verified facts
What the public records show
CMS Open Payments records show Glenn Beck, DO received $32.38 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 55.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.00 | 55.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.38 | 44.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.38 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
146 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 704 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 565 | 153 |
| Lisinopril | Lisinopril | 565 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 522 | 165 |
| Omeprazole | Omeprazole | 437 | 143 |
| Metformin Hcl | Metformin Hcl | 367 | 116 |
| Losartan Potassium | Losartan Potassium | 340 | 93 |
| Gabapentin | Gabapentin | 337 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 332 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 308 | 124 |
| Pravastatin Sodium | Pravastatin Sodium | 268 | 86 |
| Furosemide | Furosemide | 265 | 76 |
| Trazodone Hcl | Trazodone Hcl | 259 | 73 |
| Simvastatin | Simvastatin | 256 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 115 |
| Jardiance | Empagliflozin | 248 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 70 |
| Montelukast Sodium | Montelukast Sodium | 218 | 58 |
| Allopurinol | Allopurinol | 208 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 59 |
| Meloxicam | Meloxicam | 166 | 60 |
| Potassium Chloride | Potassium Chloride | 159 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 52 |
| Warfarin Sodium | Warfarin Sodium | 154 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 148 | 41 |
| Trulicity | Dulaglutide | 146 | 27 |
| Atenolol | Atenolol | 141 | 39 |
| Sertraline Hcl | Sertraline Hcl | 129 | 39 |
| Eliquis | Apixaban | 125 | 31 |
| Glimepiride | Glimepiride | 120 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 45 |
| Famotidine | Famotidine | 103 | 34 |
| Buspirone Hcl | Buspirone Hcl | 97 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 31 |
| Finasteride | Finasteride | 96 | 29 |
| Carvedilol | Carvedilol | 95 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 33 |
| Methylprednisolone | Methylprednisolone | 83 | 75 |
| Ezetimibe | Ezetimibe | 79 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 23 |
| Mirtazapine | Mirtazapine | 72 | 18 |
| Ozempic | Semaglutide | 68 | 16 |
| Metformin Hcl Er | Metformin Hcl | 62 | 20 |
| Prednisone | Prednisone | 61 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 14 |
| Nystatin | Nystatin | 59 | 25 |
| Azithromycin | Azithromycin | 58 | 53 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 18 |
| Meclizine Hcl | Meclizine Hcl | 55 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 25 |
| Bupropion Xl | Bupropion Hcl | 53 | 12 |
| Spironolactone | Spironolactone | 51 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 34 |
| Glipizide | Glipizide | 42 | 15 |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Nabumetone | Nabumetone | 38 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 17 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | 13 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 22 |
| Alendronate Sodium | Alendronate Sodium | 30 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 14 |
| Topiramate | Topiramate | 30 | 11 |
| Valsartan | Valsartan | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Klor-Con M20 | Potassium Chloride | 29 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 13 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Baclofen | Baclofen | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Ramipril | Ramipril | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.38 · 2 records | PFIZER INC. | AMYVID, ELIQUIS, KISUNLA, NURTEC ODT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error